Prototype Pulse Oximeter Targets Skin Tone Bias
The ChromaSense pulse oximeter aims to eliminate skin tone bias by using reflective light technology to provide accurate oxygen saturation readings across diverse patient populations.
The ChromaSense pulse oximeter aims to eliminate skin tone bias by using reflective light technology to provide accurate oxygen saturation readings across diverse patient populations.
The ChromaSense pulse oximeter aims to eliminate skin tone bias by using reflective light technology to provide accurate oxygen saturation readings across diverse patient populations.
Read MoreMasimo has appointed Tim Benner as president, effective August 3, 2026, according to a company news release.
Read MoreMasimo received FDA 510(k) clearance for the Patient State Index (PSi) , a new monitoring index that helps clinicians track brain activity and sedation levels in children during surgery and intensive care.
Read MoreThe new portfolio includes smart monitoring and cueing devices designed to support proactive patient care and data-driven insights.
Read MoreNew research suggests acoustic speech features can identify respiratory exacerbations from the first day of onset.
Read MoreAutonomous Healthcare received FDA De Novo marketing authorization for Syncron-E, a software that supports the assessment of patient-ventilator asynchrony by detecting evidence of ineffective efforts.
Read MoreA collaboration between Jiva.ai and Aevice Health has developed a predictive model that identifies potential asthma exacerbations up to 72 hours in advance.
Read MoreRemote monitoring did not increase the time spent at home after discharge among patients hospitalized with sepsis or lower respiratory tract infection, according to results from a randomized clinical trial of 1,286 adults.
Read MoreThe software-as-a-medical-device allows for contactless measurement of respiratory and pulse rates using only a standard smartphone camera.
Read MoreMasimo’s Radius VSM wearable monitor uses pattern recognition to help ID early signs of opioid-induced respiratory depression (OIRD).
Read MoreThe BreatheLink platform allows patients to transmit overnight oximetry data from their own smartphones, reducing the time required to set up home oxygen therapy.
Read MoreDanaher Corp completed the acquisition of Masimo Corp for $9.9 billion.
Read MoreFrom assessing hypoxia and supplemental oxygen needs in respiratory patients to screening obstructive sleep apnea and evaluating dental sleep appliances, overnight pulse oximetry (OPO) offers noninvasive, cost-effective monitoring, as new technologies further streamline care.
Read MoreResearchers developed a soft, skin-like nasal patch to track sleep apnea breathing patterns without the need for bulky tubes or wires.
Read MoreThe new suite integrates workflows for COPD, lung nodules, and pulmonary embolism to improve patient follow-up and treatment times.
Read MoreThe CO Check Pro is designed for use in both smoking cessation programs and emergency healthcare settings for the detection of carbon monoxide poisoning.
Read MoreA Mayo Clinic study demonstrates that at-home monitoring provides actionable data and reduces the travel burden for post-transplant patients.
Read MoreA Mayo Clinic study indicates that home monitoring kits can identify early complications and reduce travel burdens for transplant recipients.
Read MoreResearchers developed a contactless method using radio frequency identification (RFID) technology to track respiratory function.
Read MoreSleep metrics from wrist monitors can identify which COPD patients may need more support during pulmonary rehab.
Read MoreMasimo Corp will be acquired by Danaher Corp for $9.9 billion, according to multiple media reports including Reuters.
Read MoreZoll Medical’s Zenix monitor/defibrillator is now approved under the European Union’s Medical Device Regulation 2017/745, commonly referred to as EU MDR.
Read MoreSalaera’s MaxO2 ME+p devices are designed to help hospitals meet monitoring guidelines and improve patient safety during respiratory therapies.
Read MoreMasimo O3 Regional Oximetry is FDA-cleared for delta hemoglobin parameters, and is now available for both cerebral and somatic applications across all patient populations, including pediatric and neonatal patients.
Read More